Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Potential increased risk of PML
The FDA today informed healthcare professionals that it is investigating a potential link between the use of CellCept and Myfortic and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease. The FDA is currently reviewing data from the manufacturers of these products, and anticipates it may take about 2 months to complete this review and/or make appropriate recommendations. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111294.htm
Learn More

Selected recall of sertraline liquid oral concentrate
Boehringer Ingelheim Roxane Inc has initiated a recall of selected 60mL bottles of 20mg/mL Sertraline Hydrochloride Oral Concentrate (sometimes known as "LIQUID ZOLOFT"). These bottles are being recalled since they may not meet their shelf life expectations. The recall applies to: Sertraline Hydrochloride Oral Concentrate 20mg/mL (60mL) bottles Lot: 657694A, Expiry Sep-08 Sertraline Hydrochloride Oral Concentrate 20mg/mL (60mL) bottles Lot: 657695A, Expiry Sep-08 Sertraline Hydrochloride Oral Concentrate 20mg/mL (60mL) bottles Lot: 658085A , Expiry Jan-09
Learn More